BioPharma Dive May 8, 2024
Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
Executive decisions are often closely linked to the patent life of blockbuster medicines. Ahead of so-called patent cliffs, when patent expirations permit waves of lookalike competitors to enter the market, companies typically seek to restock their pipelines by investing in R&D, licensing experimental therapies or acquiring other drugmakers.
A major patent cliff faces the pharma industry later this decade, putting more than $200 billion in annual revenue at risk through 2030. This will...
Today's Sponsors
Today's Sponsor